Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension of Trappsol Cyclo in NPC-1
NCT03893071Phase 1Unknown
- Sponsor
- Cyclo Therapeutics, Inc.
- Start
- May 2019
- Primary completion
- Mar 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Trappsol Cyclo in Niemann-Pick disease type C (NPC), sponsored by Cyclo Therapeutics, Inc. Primary endpoints: Adverse events (AEs), Serious adverse events (SAEs) and 2 more. Status: unknown.
02
Drugs
Trappsol Cyclo
03
Conditions
Niemann-Pick disease type C (NPC)
Beyond the preview
Go deeper on NCT03893071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03893071.